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Abstract
Objectives—To evaluate whether in children born extremely preterm, indicators of sustained 
systemic inflammation in the first month of life are associated with cognitive impairment at school 
age.
Study design—873 of 966 eligible children previously enrolled in the multicenter Extremely 
Low Gestational Age Newborn Study from 2002–2004 were evaluated at age 10 years. We 
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analyzed the relationship between elevated blood concentrations of inflammation-associated 
proteins in the first 2 weeks (“early elevations”; n=812) and the 3rd and 4th week (“late 
elevations”; n=532) of life with neurocognition.
Results—Early elevations of CRP, TNF-alpha, IL-8, ICAM-1, and EPO were associated with IQ 
values >2 SD below the expected mean (ORs: 2.0–2.3) and with moderate to severe cognitive 
impairment on a composite measure of IQ and executive function (ORs: 2.1–3.6). Additionally, 
severe cognitive impairment was associated with late protein elevations of CRP (OR:4.0; 95% CI 
1.5, 10), IL-8 (OR:5.0; 1.9, 13), ICAM-1 (OR:6.5; 2.6, 16), VEGF-R2 (OR:3.2; 1.2, 8.3), and TSH 
(OR:3.1; 1.3, 7.3). Moderate cognitive impairment was most strongly associated with elevations of 
IL-8, ICAM-1, and VEGF-R2. When four or more inflammatory proteins were elevated early, the 
risk of having an IQ<70 and having overall impaired cognitive ability was more than doubled 
(ORs:2.1–2.4); the presence of four or more inflammatory protein elevated late was strongly 
linked to adverse cognitive outcomes (ORs:2.9–4.8).
Conclusion—EP children who had sustained elevations of inflammation-related proteins in the 
first postnatal month are more likely than EP peers without such elevations to have cognitive 
impairment at 10 years.
Keywords
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Advances in neonatal intensive care have increased the survival of extremely preterm 
children born before 28 weeks of gestation.(1) Little progress has been made, however, in the 
prevention of moderate to severe neurocognitive impairments that affect about 40% of EP 
survivors.(1–13) Improvement in outcomes of EP children requires a better understanding of 
the antecedents and causes of neurocognitive impairment in this population, which could 
lead to development of new technologies and approaches. In the initial phase of the 
Extremely Low Gestational Age Newborn (ELGAN) Study that evaluated more than 900 
children born before 28 weeks gestation, neonatal elevations of specific molecular 
biomarkers (ie, inflammation-associated proteins in blood), robustly predicted cognitive 
impairment at 2 years of age.(14, 15) Moreover, concentrations of inflammation-related 
proteins in blood spot samples collected in the 3rd and 4th weeks of life were associated with 
two-year outcomes beyond associations with protein concentrations from the first two 
postnatal weeks alone.(16)
Cognitive assessments at 2 years among infants born with extremely low birth weight, 
however, have correlated only modestly with school-age cognitive abilities(12, 17), which 
better predict later academic achievement and vocational and social competence.(18) For a 
more definitive evaluation of the long-term impact of neonatal elevations of inflammation-
related proteins, we assessed cognitive abilities during school age in the ELGAN Study 
cohort when assessment of cognitive ability is reliable.
We report here analyses that test the hypothesis that persistent, elevated concentrations of 
circulating inflammation-associated proteins in the first 2 postnatal weeks (early) are 
associated with an increased risk of cognitive deficits at 10 years of age in EP children. We 
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also test the hypothesis that persistent, elevated concentrations of circulating inflammation-
associated proteins in the 3rd and 4th postnatal weeks are associated with risk of cognitive 
deficits at age 10 years beyond the risk conferred by the “early” elevations of inflammatory 
proteins.
Methods
The ELGAN Study is a multicenter observational study of the risk of structural and 
functional neurologic disorders in EP infants. During the years 2002–2004, women 
delivering before 28 weeks gestation were asked to enroll in the study. A total of 1249 
mothers of 1506 infants consented to participate. At 10 years of age, 966 surviving children 
for whom we obtained neonatal blood specimens for measurement of inflammation-related 
proteins, were targeted for recruitment. The families of 889 (92%) of these children returned 
for follow up. The institutional review boards of all participating institutions approved 
enrollment and consent procedures for this follow-up study.
Of the 889 children evaluated, 11 did not accompany the parent or caregiver during the 
follow-up visit (hence informed consent could not be obtained), and 5 children did not 
cooperate with the child assessment, leaving a final sample of 873 children. In the analyses 
that included only early protein elevations, of the 873 participants, we evaluated risk in the 
812 for whom both early blood samples and 10-year outcome data were available. When we 
evaluated risk associated with late elevations (3rd and 4th postnatal week), we considered 
the risk above that attributable to the early elevations, and included only the 532 children for 
whom we possessed blood samples at both the early and late time intervals. Because of 
severe motor, visual and cognitive disability, 29 children were assigned floor scores on all 
tests, and 11 were assigned floor scores on some tests.
Families willing to participate were scheduled for one visit, usually at the institution of birth. 
Child measures were selected to provide the most comprehensive assessment of cognitive 
and academic function obtainable in a single testing session. Evaluations were administered 
by certified child psychologists blinded to clinical information in a 3 to 4 hour session that 
included breaks. All psychologist examiners underwent a 1-day in-person training and 
verification of competency for administering the neurocognitive test battery.
Assessments
General cognitive ability (or IQ) was assessed with the School-Age Differential Ability 
Scales–II (DAS-II(19), and Verbal and Nonverbal Reasoning scales. Because DAS-II Verbal 
and Nonverbal IQ scores were strongly correlated within the sample, the mean of these two 
meaures was used as an estimate of general cognitive ability.
Attention and executive function were assessed with the DAS-II and the NEPSY-II.(20). 
DAS-II Recall of Digits Backward and Recall of Sequential Order measured verbal working 
memory. NEPSY-II Auditory Attention and Auditory Response Set measured sustained 
auditory attention, set switching and inhibition. NEPSY-II Inhibition-Inhibition and 
Inhibition-Switching tasks measured simple inhibition and inhibition in the context of set 
shifting, respectively. NEPSY-II Animal Sorting measured concept generation and mental 
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flexibility. For purposes of these analyses, executive function was considered in conjunction 
with IQ using a Latent Profile Analysis construct.
We used latent profile analysis (LPA) to classify children in our sample into subgroups based 
on similarities in their profiles of IQ and EF scores. These analyses identified four 
subgroups in our cohort corresponding to overall cognitive functioning that was normal 
(34% of cohort, with mean IQ and EF scores within normal range on all measures), low-
normal (41%, with mean IQ and EF scores ranging from 0.5 to 1 standard deviation below 
the norm), moderately impaired (17%, with mean IQ and EF measures between 1.5 and 2.5 
standard deviations below the norm), and severely impaired (8%, with mean IQ and EF 
measures 3 to 4 standard deviations below the norm).
Blood Protein measurements
Drops of whole blood were collected on (Schleicher & Schuell 903) filter paper on the first 
postnatal day (range: 1–3 days) and the 7th (range: 5–8 days) and 14th (range: 12–15 days) 
postnatal days. Twenty-eight proteins taken from blood samples in the first two weeks of life 
and 16 proteins taken from blood sample in the 3rd and 4th weeks of life were measured in 
the Laboratory of Genital Tract Biology, Brigham and Women’s Hospital, using the Meso 
Scale Discovery multiplex platform and Sector Imager 2400 (Meso Scale Discovery, 
Gaithersburg, MD), which has been validated against ELISA. Details about the procedure 
for processing the blood spots and for measuring protein concentrations and absolute value 
ranges for 28 inflammation-regulating proteins are explained elsewhere.(21)
In the blood spot samples we considered for analyses the 16 proteins that were measured at 
all 5 points of time in the first month of life, including cytokines: Interleukin (IL)-1 β 
(IL-1β), Interleukin-6 (IL-6) and its receptor (IL-6R), tumor necrosis factor-alpha (TNF-α) 
and one of its receptors (TNF-alpha R2); adhesion molecules: intercellular adhesion 
molecule-1 (ICAM-1); growth factors: vascular endothelial growth factor (VEGF) and one 
of its receptors (VEGF-R2); chemokines: Interleukin-8 (IL-8), regulated upon activation, 
and normal T-lymphocyte expressed, and (presumably) secreted (RANTES); 
metalloproteinases: matrix metalloproteinase-9 (MMP-9); liver-produced: serum amyloid A 
(SAA), C-reactive protein (CRP); endocrine regulators: thyroid-stimulating hormone (TSH) 
and erythropoietin (EPO), and neutrophil- derived effectors: myeloperoxidase (MPO).
Volumes of blood spotted on the filter paper varied, and to standardize the inflammation 
protein measurements we eluted each fixed spot area in the same volume of elution buffer 
and normalized the concentration of each biomarker to total protein concentration.(22) 
Measurements were made in duplicate, and the mean served as the basis for all tables and 
analyses. The protein concentrations varied with gestational age, and with the postnatal day 
of collection.(23, 24) In addition, measurements from the first two weeks of life were assayed 
in 2009–2010 whereas the proteins obtained from weeks 3 and 4 of life were assayed in 
2015, and, although the distributions of each were similar, they were not identical. 
Consequently, we divided our sample into 30 groups defined by gestational age category 
(23–24, 25–26, 27 weeks), postnatal day of blood collection (1, 7, 14, 21 and 28), and 
measurement set (2009–2010, 2015). Four considerations prompted us to operationalize 
using highest quartile protein values for a particular gestational age and postnatal day/week 
Kuban et al. Page 4
J Pediatr. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of sampling as a measure of inflammation signal. First, normative data for circulating 
inflammation-associated proteins in extremely low gestational age newborns (ELGANs) are 
not available. Second, circulating protein concentrations in our cohort of ELGANs varied 
according to gestational age and by postnatal day or week the blood was sampled. Third, the 
protein values did not conform to a normal distribution. Finally, because weeks 3 and 4 
blood measures were completed nearly 10 years apart, use of quartile minimizes potential 
impact of protein degradation over time. Sustained elevation for a particular protein was 
defined as a protein concentration in the highest quartile on at least 2 of the 3 measures 
obtained in the first 2 weeks and in the highest quartile on both measures for the 3rd and 4th 
week samples.
Data analyses
We evaluated two measures of cognition using IQ and LPA categories. We use cognitive 
impairment as an overarching term that refers to either having impaired IQ (mean verbal and 
nonverbal IQ less than 70) or having impaired overall cognitive functioning (moderately or 
severely impaired groups based on LPA, which integrates measures of IQ and executive 
function abilities). We also present 2 intermediary categories based on IQ z-scores between 
−2 and −1 or being in the low normal group based on LPA. We tested the hypothesis that 
infants with sustained inflammation were not more likely than infants without sustained 
inflammation to have cognitive impairment at age 10 years. We defined cognitive 
impairment as IQ at least 2 Z-scores below normative expectation or as moderately or 
severely impaired by LPA.
In the analyses in which we considered the number of inflammation-related protein 
elevations as a predictor of outcome, we used a subset of 9 proteins (CRP, SAA, IL-1β, IL-6, 
TNF-α, IL-8, ICAM-1, MMP-9, VEGF) common to both the early and late protein sets. 
These proteins have been associated consistently with structural and functional neurological 
outcomes in the literature and in previous ELGAN Study analyses.(14, 25, 26)
Logistic regression and multinomial logistic regression models were used to examine the 
association between measures of inflammation and cognitive impairment, controlling for 
public insurance status at birth (as a measure of low SES) and child sex. First, we explored 
whether sustained elevation of specific, individual proteins in the first two postnatal weeks 
of life (early) predicted cognitive impairment. Second, we explored whether breadth of early 
inflammation (with high defined by the presence of sustained elevations of 4 or more 
inflammation-related proteins and moderate inflammation defined by sustained elevations in 
2–3 proteins) was associated with cognitive impairment. Finally, using time-oriented 
models, we evaluated the added contribution to risk of cognitive impairment from protein 
elevations in the 3rd and 4th weeks of life, controlling for early protein elevations.(27)
Odds ratios and 95% Confidence Intervals were used to describe associations between 
markers of inflammation and our 3 category IQ outcome (IQ z-score −2 or below, between 
−2 and −2, or above −1) and 4 category overall cognitive functioning outcome (severely 
impaired, moderately impaired, low normal function, normal cognitive function). Odds 
ratios are given for each impairment category relative to the highest functioning reference 
category
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Results
Approximately 20% of the cohort was born at 23–24 weeks, 45% were born at 25–26 weeks, 
and 34% were born at 27 weeks gestation. Seven percent (38/532) were born small for 
gestational age, and 27% (132/487) had a MDI score <70 at 2 years of age. Impaired MDI 
values were highly associated with impaired IQ and with non-normal overall cognitive 
impairment at age 10 years. Children whose mothers had indicators of low socioeconomic 
status (less than high school education, single status, and public insurance), who were non-
white, and who were male were more likely to have cognitive impairment (Table I).
In the first two weeks, elevated concentration of CRP, TNF-alpha, IL-8, ICAM-1, and EPO 
individually was associated with Impaired IQ (ORs ranging from 2.0 to 2.3). (Table II) 
These proteins, as well as CRP and SAA, also were associated with moderately and severely 
impaired overall cognitive functioning (ORs: 2.1 to 3.6 for the severly impaired group and 
from 2.0 to 2.4 for the moderately impaired group) (Table III). After adjusting for early 
protein elevations, late elevations of CRP, VEGF-R2, and TSH were associated with severe 
impairment (ORs ranged from 3.1 to 6.5). IL-8, ICAM-1, and VEGF-R2 also were 
significantly higher in the groupts testing as moderately impaired and low normal compared 
with groups testing as normal.
The presence of ≥4 elevations of inflammatory protein was associated with impaired IQ 
(OR: 2.1 to 2.4) (Table IV). Additionally, elevations of ≥4 proteins were associated with 
moderately impaired overall cognitive function (OR: 2.8; 95% CI 1.5, 5.0) and low normal 
overall cognitive function (OR: 1.7; 95% CI 1.01, 2.7).
After adjusting for early elevations of protein in the 532 children for whom we assayed 
proteins both in the early and late periods (Table IV), late elevation of ≥4 proteins was 
associated with impaired IQ, severe and moderate overall cognitive impairment, (ORs 
ranged from 2.9 to 5.1).
Among the proteins evaluated, the two most consistently associated with cognitive 
impairment were IL-8 and ICAM-1. Early elevations of these were associated with severly 
decreased IQ (IL-8-OR: 2.3;1.4,3.8; ICAM-1- OR: 2.3; 1.4,3.7) (Table II). When adjusting 
for early elevations of proteins, late elevations of these two proteins were associated with 
severe overall cognitive impairment (IL8- OR: 5.0; 1.9,13; ICAM-1- OR: 6.5;2.6,16) (Table 
III) . Both of these protein elevations also were associated with moderately impaired and low 
normal overall impairment from the LPA grouping with ORs that ranged from 2.7 to 6.3.
Discussion
Persisting, elevated concentrations of a broad number of circulating inflammation-associated 
proteins in the first 4 postnatal weeks were associated with cognitive impairment at age 10 
years. The association was found for IQ measures, and a categorical outcome that 
summarized IQ and executive function. Additionally, IL-8 and ICAM-1 were the circulating 
proteins in the first month of life most strongly associated with cognitive impairment at 10 
years of age.
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Previously, we demonstrated that persisting, elevated levels of circulating inflammation-
associated proteins in the first 2 postnatal weeks of life were associated with cognitive 
impairment at 2 years of age in the ELGAN Study cohort.(14, 15) Now we provide evidence 
that elevation of circulating inflammation-associated proteins detectable in the 3rd and 4th 
postnatal weeks contribute to risk of cognitive impairment beyond the risk posed by the 
presence of such proteins in the first 2 weeks of life(28). This observation coupled with our 
previous report, which shows little association of Day 1 inflammatory protein elevations 
with 2-year cognitive outcomes(14), suggests that in addition to exposures that initiate an 
inflammatory process in utero, postnatal exposures also might initiate inflammation that 
predicts later cognitive deficits. Such postnatal exposures could injure the brain directly and 
also could constitute a second hit to an already sensitized central nervous system.(29, 30) 
Postnatal events that can contribute to risk over the first 4 weeks of life include lung 
inflammation, necrotizing entrerocolitis, derangements of blood pressure and oxygen 
exchange, acidosis, and bacteremia, fungemia, and/or sepsis.(31–33)
The mechanisms by which inflammation contributes to neurologic dysfunction are not yet 
known, but could include microglial activation, enhanced expression of cyclooxygenase 2, 
death of immature oligodendrocyte, excitotoxic-glutamatergic-mediated injury, disruptions 
to neuronal migration and survival, and impaired synaptogenesis(34). The mechanisms may 
be more indirect, including the initiation of epigenetic-mediated changes that contribute to 
neuronal death, impededence production of neuroprotective proteins, and/or interference 
with neuroplasticity mechanisms.(29, 35–39) In addition, it is possible that disturbance of the 
infant’s systemic immune-inflammatory balance may affect the establishment of a healthy 
microbiome at birth with consequent microbiota-mediated harmful effects on the 
brain.(40, 41)
Aside from the ELGAN Study, only two studies have assessed relationships between 
inflammation-related proteins(42, 43) in neonatal blood and subsequent developmental 
outcomes; one involved infants born at less than 1 kilogram(42), and the other 67 infants born 
at less than 32 weeks gestation.(43) Both studies associated TNF-alpha with poor cognitive 
outcomes. One also identified an elevation of IL-8(42) and the other an elevation of IL-6(43) 
as associated with decreased scores on one of the two Bayley Scales of Infant Development 
at 2 years of age. A large study that evaluated proteins in cord blood(44) did not identify any 
protein elevation as being associated with low Bayley MDI or PDI. Our study differed from 
these in that we examined school age outcomes, evaluated proteins over the course of the 
first month of life, and investigated sustained elevation of proteins.
Among adults, neurologic injury after cardiac arrest or severe head trauma is associated with 
elevations of many inflammatory markers, most elevations, which resolve within 12 
hours.(45) Persisting IL-8 (and E-selectin) elevations, much as in our study, however, are 
associated with greater degrees of neurologic injury.(46) The elevations of inflammation-
related proteins early in life that are associated with later cognitive impairment appear to 
persist for weeks. Although inflammation also might be a consequence of brain injury, 
evidence suggests that the process of inflammation resolution promotes feedback-loops 
between the immune system and the brain damage,(47) leading to augmented brain damage 
and increased neurologic dysfunction.(48)
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The persistence of risk through the first 4 weeks of life and the limited risk associated with 
protein elevation on the first day of life imply a later and broader window of vulnerability 
than previously recognized, when specific therapeutic interventions targeting inflammatory 
processes might effectively decrease the risk of adverse outcomes. Therapies that can 
modulate inflammation, such as hypothermia(49), erythropoietin(50), and melatonin(50–52) 
show promise as strategies to improve brain-related outcomes in newborns. 
Inflammation(53–55), developmental regulation of immunity(56), immune response to 
infections(57), and stress-induced immune dysregulation(58) may be influenced by epigenetic 
alterations that activate the expression of pro-inflammatory cytokines. Pharmacologic agents 
that target epigenetic processes (e.g. histone deacteylase inhibitors(59–61) and folate, a one-
carbon donor for DNA methlhylation(62)) show promise as therapies for dampening 
inflammation or its effects in the postnatal period.
Our data suggest that IL-8 and ICAM-1 are important risk modulators for cognitive 
outcome. IL-8, a chemokine, previously has been implicated as a marker of adverse 
neurologic outcomes in preterm newborns(63, 64) and in adults following cardiac arrest(65). 
IL-8 plays a role in acute inflammation by recruiting and activating neutrophils(66) and 
specifically has been associated with increased risk of psychomotor development index < 
70(42). ICAM-1 is an adhesion molecule and is thought to play a crucial role in the 
pathogenesis of inflammation. Simvastatin reduces expression of ICAM-1 and has been 
associated with improved outcomes in a rat model of traumatic brain injury(67). Elevations of 
ICAM-1 in humans with stroke have been associated with more severe neurologic 
deficits(68, 69). Both IL-8 and ICAM-1 also specifically were elevated in our cohort of 
infants with cerebral white matter injury and/or intraventricular hemorrhage on early head 
ultrasound studies(27, 70), and in children at age 2 years with microcephaly(26), abnormal 
cognition(14), attentional disorders(71), and cerebral palsy(25).
The association of later adverse outcomes with the presence of early-life circulating 
inflammatory proteins probably is modulated by other factors associated with immaturity, 
including the availability of endogenous protective factors (72),(73),(74), such as oligotrophins. 
Heightened production and availability of oligotrophins could modulate the damaging 
effects associated with inflammation, for example, by enhancing cell development and/or 
survival (73). In this report we focus on risk associated with cytokines and other effectors of 
acute inflammation, but a clearer understanding of the relationship of inflammation to 
neuronal risk and later cognitive consequences could derive from consideration of 
endogenous protectors as well.
Our study has several strengths. We included a large number of infants, collected our data 
prospectively, had only modest attrition across 10 years of follow-up, examiners at 2 and 10 
years were not aware of the medical histories of the children they examined, and measured 
protein data are of high quality, with high content validity.(22, 23, 75)
A limitations of an observational study is that causation and association of study findings 
cannot be distinguished. Although we sampled a wide range of inflammation-associated 
proteins, including specific proteins known to be associated with neurologic damage, we did 
not evaluate all known inflammation-associated proteins. We selected proteins on the basis 
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of likely involvement in the fetal/neonatal inflammatory response and the accuracy with 
which they could be measured reliably in whole blood spots using the Meso Scale Discovery 
multiplex platform. It is likely that the 532 children who underwent late protein assessments 
were more ill than those who no longer required blood samples. Even though this probably 
does not bias associations, it could limit the degree to which these associations can be 
generalized to healthier preterm infants. Finally, rather than report absolute protein 
concentration values, we used a distribution-based definition of protein elevation according 
to gestational age, postnatal day, and the interval between processing blood samples, 
because normal values are not known and values appear to be influenced by these factors.
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ELGAN Extremely low gestational age newborn
NICU Neonatal intensive care unit
BSID-II Bayley Scales of Infant Development - Second Edition
MDI mental development index of the BSID-II
PDI psychomotor development index of the BSID-II
CRP C-Reactive Protein
E-sel E-selectin
EPO Erythropoietin
IL-1β Interleukin-1β
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ICAM-3 Intercellular Adhesion Molecule −3
IGFBP-1 Insulin-like growth factor binding protein-1
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I-TAC Interferon-inducible T cell alpha-chemoattractant
MMP-9 Matrix Metalloproteinase-9
MCP-1 Monocyte chemotactic protein-1
MCP-4 Monocyte chemotactic protein-4
MIP-1 beta Macrophage inflammatory protein-1beta
MMP-1 Metalloproteinase-1
MMP-9 Metalloproteinase-9
MPO Myeloperoxidase
RANTES Regulated upon Activation, Normal T-cell Expressed, and 
Secreted
SAA Serum Amyloid A
TNF-α Tumor Necrosis Factor-α
TNF-R2 Tumor Necrosis Factor Receptor-1
TNF-R1 Tumor Necrosis Factor Receptor-2
TSH thyroid-stimulating hormone
VCAM-1 Vascular cell adhesion molecule-1
VEGF Vascular Endothelial Growth Factor Receptor-1
VEGF-R1 Vascular Endothelial Growth Factor Receptor-2
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Table 2
Adjusted odds ratios1 and 95% confidence intervals for impaired IQ2 at age 10 years for those with elevated 
inflammatory protein concentrations3 on 2 of the first 3 postnatal measurements (n=809)4.
N DAS IQ Z-score
Elevated/
Not Elevated
≤ −2
(n=125)
> −2, ≤ −1
(n=153)
CRP 155 / 654 2.0 (1.2, 3.2) 1.4 (0.9, 2.2)
SAA 133 / 676 1.6 (0.97, 2.7) 1.5 (0.9, 2.4)
MPO 142 / 667 1.0 (0.6, 1.6) 1.1 (0.7, 1.7)
IL-1β 132 / 677 1.6 (0.98, 2.7) 1.1 (0.6, 1.8)
IL-6 131 / 678 2.0 (1.2, 3.3) 1.2 (0.8, 2.0)
IL-6R 161 / 648 0.7 (0.4, 1.2) 1.1 (0.7, 1.7)
TNF-α 154 / 655 2.0 (1.2, 3.2) 1.6 (1.00, 2.4)
TNF-R2 138 / 671 1.3 (0.8, 2.1) 1.0 (0.6, 1.7)
IL-8 (CXCL8) 136 / 673 2.3 (1.4, 3.8) 1.6 (1.02, 2.6)
RANTES (CCL5) 149 / 660 0.7 (0.4, 1.2) 0.7 (0.4, 1.2)
ICAM-1 (CD54) 152 / 687 2.3 (1.4, 3.7) 1.5 (0.9, 2.3)
MMP-9 122 / 687 0.7 (0.4, 1.3) 0.9 (0.6, 1.6)
VEGF 164 / 645 0.7 (0.4, 1.1) 0.9 (0.6, 1.4)
VEGF-R2 164 / 645 1.1 (0.7, 1.8) 1.2 (0.8, 1.9)
TSH 164 / 645 1.2 (0.7, 1.9) 1.0 (0.6, 1.5)
EPO 138 / 671 2.2 (1.3, 3.5) 1.4 (0.9, 2.3)
1Odds ratios comparing indicated IQ group to those with IQ Z-score above −1, adjusting for public insurance and child sex through multinomial 
logistic regression
2
IQ z-score based on average of the DASII verbal and non-verbal IQ scores
3
Inflammatory protein concentration in the top quartile controlling for gestational age and day of measurement
43 children completed only the verbal or nonverbal IQ, so an average could not be calculated
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